Lyell Immunopharma Inc (LYEL)

$21.21 +0.40 (1.92%)
Market Cap 494.34M
Revenue (ttm) 40,000.00
Net Income (ttm) -274.45M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -686,125.05%
Debt to Equity Ratio 0.00
Volume 88,800
Avg Vol 99,128
Day's Range N/A - N/A
Shares Out 23.31M
Stochastic %K 83%
Beta -0.06
Analysts Sell
Price Target $32.50

Company Profile

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company's lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which i...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 695 0677
Address:
201 Haskins Way, Suite 101, South San Francisco, United States
Hopipaytrader
Hopipaytrader Mar. 24 at 4:59 PM
$LYEL 200 dma magnet
0 · Reply
SuperGreenToday
SuperGreenToday Mar. 24 at 3:58 PM
$LYEL Share Price: $19.54 Contract Selected: Jul 17, 2026 $20 Calls Buy Zone: $1.27 – $1.58 Target Zone: $2.14 – $2.62 Potential Upside: 59% ROI Time to Expiration: 114 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
terra987
terra987 Mar. 23 at 2:57 PM
$LYEL 13$ - wishful thinking
0 · Reply
Peterson28
Peterson28 Mar. 20 at 6:39 PM
$LYEL Told you. The in and out flow has shown that. This will be retesting 52-week lows before another pump by MMs. Buying back at 13-15ish.
0 · Reply
Nanu108
Nanu108 Mar. 19 at 4:37 AM
$LYEL in for 2000 shares.
0 · Reply
Hopipaytrader
Hopipaytrader Mar. 19 at 2:49 AM
$LYEL 200dma incoming
0 · Reply
Mdugs
Mdugs Mar. 18 at 4:15 PM
$LYEL adding more today.
0 · Reply
terra987
terra987 Mar. 17 at 12:32 PM
$LYEL The reaction to the 2025 results was surprising, but still nonsense. It seems there is institutional accumulation, especially yesterday. I've added some.
0 · Reply
Ron13699
Ron13699 Mar. 11 at 2:16 PM
$LYEL Shit
2 · Reply
BillionerOfKing
BillionerOfKing Mar. 10 at 5:32 PM
$LYEL Current Stock Price: $26.43 Contracts to trade: $26.0 LYEL Mar 20 2026 Call Entry: $0.10 Exit: $0.13 ROI: 25% Hold ~22 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Latest News on LYEL
Lyell Immunopharma: Strong Early CAR-T Data, And Now A More Measured Bet

Mar 23, 2026, 4:37 PM EDT - 12 days ago

Lyell Immunopharma: Strong Early CAR-T Data, And Now A More Measured Bet

Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results

Mar 12, 2026, 4:05 PM EDT - 23 days ago

Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results

Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer

Mar 9, 2026, 8:00 AM EDT - 27 days ago

Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer

Lyell Immunopharma, Inc. (LYEL) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Mar 6, 2026, 4:55 PM EST - 4 weeks ago

Lyell Immunopharma, Inc. (LYEL) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Lyell Immunopharma Announces Participation in March Investor Conferences

Feb 23, 2026, 8:00 AM EST - 5 weeks ago

Lyell Immunopharma Announces Participation in March Investor Conferences

Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell Lymphoma

Feb 12, 2026, 7:30 AM EST - 7 weeks ago

Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell Lymphoma

Lyell Immunopharma: LYL314 Drives Momentum Amid Strong ASH Data

Dec 24, 2025, 8:30 AM EST - 3 months ago

Lyell Immunopharma: LYL314 Drives Momentum Amid Strong ASH Data

Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition

Dec 7, 2025, 4:30 PM EST - 4 months ago

Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025

Nov 12, 2025, 4:05 PM EST - 5 months ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025

Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer

Nov 10, 2025, 7:30 AM EST - 5 months ago

Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer

Lyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lymphoma at the 67th ASH Annual Meeting and Exposition

Nov 3, 2025, 9:00 AM EST - 5 months ago

Lyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lymphoma at the 67th ASH Annual Meeting and Exposition

Lyell Immunopharma Announces the Initiation of a Phase 3 Head-to-Head CAR T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma and Formation of Expert Steering Committee

Sep 3, 2025, 8:00 AM EDT - 7 months ago

Lyell Immunopharma Announces the Initiation of a Phase 3 Head-to-Head CAR T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma and Formation of Expert Steering Committee

Lyell Immunopharma Announces Participation in September Investor Conferences

Sep 2, 2025, 4:05 PM EDT - 7 months ago

Lyell Immunopharma Announces Participation in September Investor Conferences

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025

Aug 12, 2025, 4:05 PM EDT - 8 months ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025

Lyell Immunopharma Announces up to $100 Million Equity Private Placement

Jul 25, 2025, 8:00 AM EDT - 9 months ago

Lyell Immunopharma Announces up to $100 Million Equity Private Placement

Lyell: 'Hold' Rating Based On Phase 3 LYL314 LBCL Treatment Program Advancement

Jul 22, 2025, 9:02 AM EDT - 9 months ago

Lyell: 'Hold' Rating Based On Phase 3 LYL314 LBCL Treatment Program Advancement

Lyell Immunopharma to Participate in the H.C. Wainwright “HCW@Home” Series

Jun 23, 2025, 5:00 PM EDT - 10 months ago

Lyell Immunopharma to Participate in the H.C. Wainwright “HCW@Home” Series

Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma

Jun 17, 2025, 6:30 AM EDT - 10 months ago

Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma

Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments

Jun 9, 2025, 4:05 PM EDT - 10 months ago

Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments

Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference

Jun 4, 2025, 4:05 PM EDT - 10 months ago

Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025

May 13, 2025, 4:05 PM EDT - 11 months ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025

Lyell Immunopharma Announces Oral Presentation of New Clinical Data from the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) 2025

May 1, 2025, 9:00 AM EDT - 1 year ago

Lyell Immunopharma Announces Oral Presentation of New Clinical Data from the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) 2025

Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma

Apr 15, 2025, 9:00 AM EDT - 1 year ago

Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024

Mar 11, 2025, 4:05 PM EDT - 1 year ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024

Lyell Immunopharma Announces Participation in Upcoming Investor Conferences

Feb 18, 2025, 4:05 PM EST - 1 year ago

Lyell Immunopharma Announces Participation in Upcoming Investor Conferences

Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference

Jan 9, 2025, 9:00 AM EST - 1 year ago

Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference

Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting

Dec 9, 2024, 9:00 PM EST - 1 year ago

Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting

Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting

Nov 5, 2024, 9:30 AM EST - 1 year ago

Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting

Lyell Immunopharma Completes Acquisition of ImmPACT Bio

Oct 31, 2024, 4:00 PM EDT - 1 year ago

Lyell Immunopharma Completes Acquisition of ImmPACT Bio

Lyell Immunopharma: Oversold And Poised For A Turning Point To Growth

Oct 25, 2024, 9:24 AM EDT - 1 year ago

Lyell Immunopharma: Oversold And Poised For A Turning Point To Growth

Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies

Oct 24, 2024, 4:00 PM EDT - 1 year ago

Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies

Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Oct 4, 2024, 9:00 AM EDT - 1 year ago

Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Lyell Immunopharma Announces Participation in Goldman Sachs Cell Therapy Day

Sep 24, 2024, 4:05 PM EDT - 1 year ago

Lyell Immunopharma Announces Participation in Goldman Sachs Cell Therapy Day

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024

Aug 7, 2024, 4:05 PM EDT - 1 year ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024

Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology

Jun 26, 2024, 7:00 AM EDT - 1 year ago

Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology

Lyell Immunopharma to Participate in BofA Securities Health Care Conference

May 7, 2024, 4:05 PM EDT - 2 years ago

Lyell Immunopharma to Participate in BofA Securities Health Care Conference

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024

May 6, 2024, 8:00 AM EDT - 2 years ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024

Lyell Immunopharma: Testing The T-Cell Thesis With 2 Upcoming Data Catalysts

Apr 16, 2024, 6:25 PM EDT - 2 years ago

Lyell Immunopharma: Testing The T-Cell Thesis With 2 Upcoming Data Catalysts

Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting

Mar 5, 2024, 4:30 PM EST - 2 years ago

Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023

Feb 28, 2024, 4:05 PM EST - 2 years ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023

Lyell Immunopharma to Participate in 42nd Annual J.P. Morgan Healthcare Conference

Jan 3, 2024, 4:05 PM EST - 2 years ago

Lyell Immunopharma to Participate in 42nd Annual J.P. Morgan Healthcare Conference

Lyell Immunopharma: Potential Solid Tumor Targeting With CAR-T And TIL

Nov 10, 2023, 2:23 PM EST - 2 years ago

Lyell Immunopharma: Potential Solid Tumor Targeting With CAR-T And TIL

Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma

Nov 9, 2023, 4:05 PM EST - 2 years ago

Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023

Nov 7, 2023, 4:05 PM EST - 2 years ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023

Lyell Immunopharma Announces the Acceptance of Six Abstracts for Presentation at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Sep 27, 2023, 9:00 AM EDT - 2 years ago

Lyell Immunopharma Announces the Acceptance of Six Abstracts for Presentation at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Cellares and Lyell to Evaluate Automated Manufacturing of Lyell's CAR T-Cell Therapy on Cellares' Cell Shuttle Platform

Sep 11, 2023, 8:00 AM EDT - 2 years ago

Cellares and Lyell to Evaluate Automated Manufacturing of Lyell's CAR T-Cell Therapy on Cellares' Cell Shuttle Platform

Lyell Immunopharma to Participate in Upcoming Investor Conferences

Aug 31, 2023, 4:05 PM EDT - 2 years ago

Lyell Immunopharma to Participate in Upcoming Investor Conferences

Lyell Immunopharma: Once Huge IPO Now Waiting For Clinical Data

Aug 26, 2023, 9:29 AM EDT - 2 years ago

Lyell Immunopharma: Once Huge IPO Now Waiting For Clinical Data

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2023

Aug 8, 2023, 4:05 PM EDT - 2 years ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2023

Lyell Immunopharma Appoints Matthew Lang as Chief Business Officer

Jul 5, 2023, 4:05 PM EDT - 2 years ago

Lyell Immunopharma Appoints Matthew Lang as Chief Business Officer

Hopipaytrader
Hopipaytrader Mar. 24 at 4:59 PM
$LYEL 200 dma magnet
0 · Reply
SuperGreenToday
SuperGreenToday Mar. 24 at 3:58 PM
$LYEL Share Price: $19.54 Contract Selected: Jul 17, 2026 $20 Calls Buy Zone: $1.27 – $1.58 Target Zone: $2.14 – $2.62 Potential Upside: 59% ROI Time to Expiration: 114 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
terra987
terra987 Mar. 23 at 2:57 PM
$LYEL 13$ - wishful thinking
0 · Reply
Peterson28
Peterson28 Mar. 20 at 6:39 PM
$LYEL Told you. The in and out flow has shown that. This will be retesting 52-week lows before another pump by MMs. Buying back at 13-15ish.
0 · Reply
Nanu108
Nanu108 Mar. 19 at 4:37 AM
$LYEL in for 2000 shares.
0 · Reply
Hopipaytrader
Hopipaytrader Mar. 19 at 2:49 AM
$LYEL 200dma incoming
0 · Reply
Mdugs
Mdugs Mar. 18 at 4:15 PM
$LYEL adding more today.
0 · Reply
terra987
terra987 Mar. 17 at 12:32 PM
$LYEL The reaction to the 2025 results was surprising, but still nonsense. It seems there is institutional accumulation, especially yesterday. I've added some.
0 · Reply
Ron13699
Ron13699 Mar. 11 at 2:16 PM
$LYEL Shit
2 · Reply
BillionerOfKing
BillionerOfKing Mar. 10 at 5:32 PM
$LYEL Current Stock Price: $26.43 Contracts to trade: $26.0 LYEL Mar 20 2026 Call Entry: $0.10 Exit: $0.13 ROI: 25% Hold ~22 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
svb64
svb64 Mar. 9 at 9:53 PM
$LYEL news?
0 · Reply
Mdugs
Mdugs Mar. 9 at 4:47 PM
$LYEL hurray
0 · Reply
terra987
terra987 Mar. 3 at 1:35 PM
$LYEL Uptrend
0 · Reply
thetaowen
thetaowen Feb. 20 at 3:59 PM
$LYEL Lyell Immunopharma develops T-cell therapies. Clinical execution drives valuation. Development risk remains high.
0 · Reply
MaryThomas194
MaryThomas194 Feb. 18 at 12:42 PM
$LYEL Cell therapy biotech with platform potential; cash runway defines risk profile.
0 · Reply
Mdugs
Mdugs Feb. 17 at 5:19 PM
$LYEL hmm?
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 13 at 6:15 PM
$LYEL RSI: 57.84, MACD: -0.4098 Vol: 1.07, MA20: 24.47, MA50: 27.59 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
TheTradeXchange
TheTradeXchange Feb. 12 at 12:31 PM
$LYEL - Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell Lymphoma
0 · Reply
Mdugs
Mdugs Feb. 10 at 7:19 PM
$LYEL back in at 22.5 will average down lower but holding strong and I am riding til the end from here. Almost doubled my shares from the last run so I’m happy. GL
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 5 at 11:19 PM
$LYEL RSI: 48.79, MACD: -0.8738 Vol: 0.86, MA20: 24.30, MA50: 27.39 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
NVDAMillionaire
NVDAMillionaire Feb. 4 at 5:29 PM
$LYEL Great piece that accurately captures LYEL's current position. So if you want to refresh your understanding of LYEL or learn about LYEL for the first time, this is essential reading. https://everyticker.com/quote/LYEL/analysis/lyell-immunopharma-s-manufacturing-edge-meets-clinical-trial-risk-nasdaq-lyel
0 · Reply
PortfolioPrince
PortfolioPrince Feb. 4 at 4:06 PM
$LYEL is a clinical-stage biotech (Lyell Immunopharma) developing cell therapies for cancer; its pipeline is early-stage and utilizes novel but unproven technologies to overcome cell therapy resistance.
0 · Reply